Neurogene Inc
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disea… Read more
Neurogene Inc (NGNE) - Total Assets
Latest total assets as of September 2025: $287.83 Million USD
Based on the latest financial reports, Neurogene Inc (NGNE) holds total assets worth $287.83 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Neurogene Inc - Total Assets Trend (2011–2024)
This chart illustrates how Neurogene Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Neurogene Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Neurogene Inc's total assets of $287.83 Million consist of 94.1% current assets and 5.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 40.7% |
| Accounts Receivable | $648.00K | 0.2% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2011–2024)
This chart illustrates how Neurogene Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Neurogene Inc's current assets represent 94.1% of total assets in 2024, a decrease from 96.0% in 2011.
- Cash Position: Cash and equivalents constituted 40.7% of total assets in 2024, down from 93.5% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 1.0% in 2011.
- Asset Diversification: The largest asset category is accounts receivable at 0.2% of total assets.
Neurogene Inc Competitors by Total Assets
Key competitors of Neurogene Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Neurogene Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Neurogene Inc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Neurogene Inc is currently not profitable relative to its asset base.
Neurogene Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 18.39 | 9.09 | 24.66 |
| Quick Ratio | 18.39 | 9.09 | 24.66 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $255.81 Million | $ 127.85 Million | $ 186.63 Million |
Neurogene Inc - Advanced Valuation Insights
This section examines the relationship between Neurogene Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.01 |
| Latest Market Cap to Assets Ratio | 0.33 |
| Asset Growth Rate (YoY) | 50.8% |
| Total Assets | $335.73 Million |
| Market Capitalization | $109.83 Million USD |
Valuation Analysis
Below Book Valuation: The market values Neurogene Inc's assets below their book value (0.33 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Neurogene Inc's assets grew by 50.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Neurogene Inc (2011–2024)
The table below shows the annual total assets of Neurogene Inc from 2011 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $335.73 Million | +50.84% |
| 2023-12-31 | $222.57 Million | +103.70% |
| 2022-12-31 | $109.27 Million | +7.66% |
| 2021-12-31 | $101.49 Million | -51.79% |
| 2020-12-31 | $210.52 Million | +43.19% |
| 2019-12-31 | $147.02 Million | +89.42% |
| 2018-12-31 | $77.62 Million | -29.65% |
| 2017-12-31 | $110.33 Million | -28.53% |
| 2016-12-31 | $154.38 Million | +36.21% |
| 2015-12-31 | $113.34 Million | +173.62% |
| 2014-12-31 | $41.42 Million | -29.52% |
| 2013-12-31 | $58.77 Million | +2409.35% |
| 2012-12-31 | $2.34 Million | -76.31% |
| 2011-12-31 | $9.88 Million | -- |